Compare Synopsys, Inc. (SNPS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Zoetis Inc — how do they compare? Synopsys, Inc. trades at $393.7 (market cap $75.13B), while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Synopsys, Inc. is far larger — about 2.5× Zoetis Inc's market cap, and Zoetis Inc pays a 2.88% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNPS | ZTS | |
|---|---|---|
Market Cap | $75.13B | $30.40B |
Sector | Technology | Health |
52-Week High | $534.56 | $150.61 |
52-Week Low | $372.33 | $71.91 |
Enterprise Value | $82.36B | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.91 versus $3.67 expected. Revenue growth remains strong, with fiscal 2025 revenue reaching $7.05 billion, though net income margin compressed to 11.43% in 2026. Analyst consensus is overwhelmingly bullish with a $541.88 price target, representing significant upside potential.
The outlook for SNPS is positive based on fundamental strength and Wall Street optimism, but risks include high valuation multiples (P/E of 68.42), competitive pressures in semiconductor software, and integration challenges from the Ansys acquisition. The stock's near-term performance will hinge on Q3 2026 earnings results and continued execution in the expanding AI-driven chip design market.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
